High glycine levels are associated with prepulse inhibition deficits in chronic schizophrenia patients

Schizophrenia Research

Volumn 91, Issue 1-3, 2007, Pages 14-21

  Heresco Levy, Uriel ^a,b   Bar, Gali ^a   Levin, Raz ^a   Ermilov, Marina ^a   Ebstein, Richard P ^a,c   Javitt, Daniel C ^d,e  

^a HERZOG HOSPITAL   (Israel)

^b HEBREW UNIVERSITY   (Israel)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^d NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^e NEW YORK UNIVERSITY   (United States)

Author keywords

Glycine levels; NMDAR modulators; PPI; Schizophrenia

Indexed keywords

GLYCINE; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; SERINE;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; ELECTROMYOGRAPHY; EYELID REFLEX; FEMALE; HUMAN; MALE; NEGATIVE SYNDROME; NEUROTRANSMISSION; PREPULSE INHIBITION; PRIORITY JOURNAL; SCHIZOPHRENIA; SCORING SYSTEM; SENSORIMOTOR FUNCTION; STARTLE REFLEX; SYMPTOMATOLOGY; VALIDITY;

ADULT; BLINKING; CHRONIC DISEASE; ELECTROMYOGRAPHY; FEMALE; GLUTAMIC ACID; GLYCINE; HUMANS; INHIBITION (PSYCHOLOGY); KETAMINE; MALE; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; STARTLE REACTION;

EID: 33847256383     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2006.12.003     Document Type: Article

References (37)

1. Abel K.M., Allin M.P.G., Hemsley D.R., and Geyer M.A. Low dose ketamine increases prepulse inhibition in healthy men. Neuropharmacology 44 (2003) 729-737
2. Andreasen N.C. Modified Scale for the Assessment of Negative Symptoms (SANS) (1984), University of Iowa, Iowa City
3. Braff D.L., and Freedman R. Endophenotypes in studies of the genetics of schizophrenia. In: Davis K.L., Charney D.S., Coyle J.T., and Nemeroff C. (Eds). Neuropsychopharmacology: The Fifth Generation of Progress (2002), Lippincott Williams & Wilkins, Philadelphia 703-716
4. Braff D.L., and Geyer M.A. Sensorimotor gating and schizophrenia: human and animal model studies. Arch. Gen. Psychiatry 47 (1990) 181-188
5. Braff D.L., Stone C., Callaway E., Geyer M.A., Glick I., and Bali L. Prestimulus effects on human startle reflex in normals and schizophrenics. Psychophysiology 15 (1978) 339-343
6. Braff D.L., Grillon C., and Geyer M.A. Gating and habituation of the startle reflex in schizophrenic patients. Arch. Gen. Psychiatry 49 (1992) 206-215
7. Braff D.L., Geyer M.A., and Swerdlow N.R. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology 156 (2001) 234-258
8. Breier A., Malhotra A.K., Pinals D.A., Weisenfeld N., and Pickar D. Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am. J. Psychiatry 154 (1997) 805-811
9. Canal N.M., Gourevitch R., and Sandner G. Non-monotonic dependency of PPI on temporal parameters: differential alteration by ketamine and MK-801 as opposed to apomorphine and DOI. Psychopharmacology 156 (2001) 169-176
10. D'Souza D.C., Charney D.S., and Krystal J.H. Glycine site agonists of the NMDA receptor: a review. CNS Drug Rev. 1 (1995) 150-186
11. D'Souza D.C., Gil R., Cassello K., Morrissey K., Abi-Saab D., White J., Sturwold R., Bennett A., Karper L.P., Zuzorte E., Charney D.S., and Krystal J.H. IV glycine and oral d-cycloserine effects on plasma and CSF amino acids in healthy humans. Biol. Psychiatry 47 (2000) 450-462
12. Duncan E.J., Madonick S.H., Parwani A., Angrist B., Rajan R., Chakravorty S., Efferen T., Szilagyi S., Stephanides M., Chappel P.B., Gonzenbach S., Ko G.N., and Rotrosen J.P. Clinical and sensorimotor gating effects of ketamine in normals. Neuropsychopharmacology 25 (2001) 72-83
13. Fendt M., Li L., and Yeomans J.S. Brain stem circuits mediating prepulse inhibition of the startle reflex. Psychopharmacology 156 (2001) 216-224
14. Geyer M.A., Krebs-Thomson K., Braff D.L., and Swerdlow N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 156 (2001) 117-154
15. Graham F.K. The more or less startling effects of weak prestimulation. Psychophysiology 12 (1975) 238-248
16. Hashimoto K., Fukushima T., Shimizu E., Komatgsu N., Watanabe H., Shinoda N., Nakazato M., Kumakiri C., Okada S., Hasegawa H., Imai K., and Iyo M. Decreased serum levels of d-serine in patients with schizophrenia. Arch. Gen. Psychiatry 60 (2003) 572-576
17. Heresco-Levy U. Glutamatergic neurotransmission modulators as emerging new drugs for schizophrenia. Expert Opin. Emerg. Drugs 10 (2005) 827-844
18. Heresco-Levy U., Javitt D.C., Ermilov M., Mordel C., Silipo G., and Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch. Gen. Psychiatry 56 (1999) 29-36
19. Hoffman H.S., and Fleshler M. Startle reaction: modification by background acoustic stimulation. Science 141 (1963) 928-930
20. Hoffman H.S., and Searle J.L. Acoustic and temporal factors in the evocation of startle. J. Acoust. Soc. Am. 43 (1968) 269-282
21. Ison J.R., McAdam D.W., and Hammond G.R. Latency and amplitude changes in the acoustic startle reflex produced by variations in auditory prestimulation. Physiol. Behav. 10 (1973) 1035-1039
22. Javitt D.C. Glutamate as a therapeutic target in psychiatric disorders. Mol. Psychiatry 9 11 (2004) 1-4
23. Javitt D.C., and Lindsley R.W. Effects f phencyclidine on prepulse inhibition of acoustic startle response in the macaque. Psychophysiology 156 (2001) 165-168
24. Kay S.R., Fiszbein A., and Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 13 (1987) 261-276
25. Krystal J.H., D'Souza D.C., Mathalon D., Perry E., Belger A., and Hoffman R. NMDA receptor antagonist effects, cortical glutamatergic function and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology 169 (2003) 215-233
26. Linn G.S., Negi S.S., Gerum S.V., and Javitt D.C. Reversal of phencyclidine-induced prepulse inhibition deficits by clozapine in monkeys. Psychopharmacology (Berl.) 169 (2003) 234-239
27. Malhotra A.K., Pinals D.A., Weingartner H., Sirocco K., Missar C.D., Pickar D., and Breier A. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 14 (1996) 301-307
28. Mansbach R.S., Geyer M.A., and Braff D.L. Dopaminergic stimulation disrupts sensorimotor gating in the rat. Psychopharmacology 94 (1988) 507-514
29. McGhie A., and Chapman J. Disorders of attention and perception in early schizophrenia. Br. J. Med. Psychol. 34 (1961) 102-116
30. Neeman G., Blanaru M., Bloch B., Kremer I., Ermilov M., Javitt D.C., and Heresco-Levy U. Relation of plasma glycine, serine and homocysteine levels to schizophrenia symptoms and medication type. Am. J. Psychiatry 162 (2005) 1738-1740
31. Perry W., and Braff D.L. Information processing deficits and thought disorder in schizophrenia. Am. J. Psychiatry 151 (1994) 363-367
32. Perry W., Geyer M.A., and Braff D.L. Sensorimotor gating and thought disturbance measured in close temporal proximity in schizophrenic patients. Arch. Gen. Psychiatry 56 (1999) 277-281
33. Sumiyoshi T., Anil Elif A., Yin D., Jayathialke K., Lee M., and Meltzer H.Y. Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms. Int. J. Neuropsychopharmacol. 7 (2004) 1-8
34. Swerdlow N.R., Geyer M.A., and Braff D.L. Neural circuitry of prepulse inhibition of startle in the rat: current knowledge and future challenges. Psychopharmacology 156 (2001) 194-215
35. Van Berckel B.N.M., Oranje B., van Ree J.M., Verbaten M.N., and Kahn R.S. The effects of low dose ketamine on sensory gating, neuroendocrine secretion and behavior in healthy human subjects. Psychopharmacology 137 (1998) 271-281
36. Waziri R., and Baruah S. A hyperglycinergic rat model for the pathogenesis of schizophrenia: preliminary findings. Schizophr. Res. 37 (1999) 205-215
37. Yong Q., Slocum R.H., Fu J., Rasmussen W.E., Rector H.D., Miller J.B., and Coldwell J.G. Quantitative amino acid analysis using a Beckman system gold HPLC 126AA analyzer. Clin. Chim. Acta 312 (2001) 153-162